Inari Medical Inc
NASDAQ:NARI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (8.1), the stock would be worth $79.45 (1% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.1 | $79.97 |
0%
|
| 3-Year Average | 8.1 | $79.45 |
-1%
|
| 5-Year Average | 8.1 | $79.97 |
0%
|
| Industry Average | 1.7 | $17.15 |
-79%
|
| Country Average | 2.4 | $23.95 |
-70%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$4.7B
|
/ |
Oct 2024
$574.5m
|
= |
|
|
$4.7B
|
/ |
Dec 2024
$615.6m
|
= |
|
|
$4.7B
|
/ |
Dec 2025
$728.5m
|
= |
|
|
$4.7B
|
/ |
Dec 2026
$854.6m
|
= |
|
|
$4.7B
|
/ |
Dec 2027
$1B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Inari Medical Inc
NASDAQ:NARI
|
4.7B USD | 8.1 | -59.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 16 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 3.5 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 4.8 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 2.9 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 4.1 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 7.5 | 43 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 10.3 | 41.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 1.7 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 1.9 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 5.7 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Inari Medical Inc
Glance View
Inari Medical Inc., nestled in the heart of Irvine, California, embarked on a mission to revolutionize the treatment for venous diseases with a sense of urgency and ingenuity. Founded in 2011, this medical device company has become a beacon of innovation in the healthcare sector, relentlessly focused on addressing the unmet needs in the treatment of venous thromboembolism (VTE) conditions, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These life-threatening conditions impact millions globally, presenting a critical challenge that Inari aims to tackle head-on. Their pioneering spirit is showcased in their flagship devices—the FlowTriever and ClotTriever—designed to remove large clots with less risk compared to traditional, invasive surgical methods. By providing minimally invasive mechanical thrombectomy devices, Inari Medical has streamlined treatments to improve patient outcomes, ultimately reducing the burden on healthcare systems. Revenue streams at Inari are intrinsically tied to their innovative products, which are integral in modern therapeutic strategies for clot removal. The commercial success of FlowTriever and ClotTriever is driven by their effectiveness and safety profile, appealing to hospitals and medical professionals looking for advanced solutions to treat VTE. Inari's business model thrives on the sales and adoption of these devices, supported by robust clinical evidence that underpins their efficacy. With a blend of aggressive research and development, education programs for physicians, and a strategic global market expansion, Inari Medical is poised to continue growing in the med-tech sector. Their commitment to addressing large medical needs with cutting-edge solutions not only defines their financial blueprint but also underscores their dedication to transforming patient care across the globe.